Crescentic glomerulonephritis associated with myeloperoxidase-antineutrophil-cytoplasmic antibodies: First report on the efficacy of primary anti-TNF-α treatment

International Journal of Tissue Reactions

Volumn 26, Issue 3-4, 2004, Pages 85-92

  Zaenker, M ^a   Arbach, O ^b   Helmchen, U ^c   Glorius, P ^a   Ludewig, S ^a   Braasch, E ^a  

^a Klinikum Barnim GmbH   (Germany)

^b German Rheumatism Research Center   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTIRHEUMATIC AGENT; ATORVASTATIN; AZATHIOPRINE; CALCIUM; COLECALCIFEROL; CORTICOSTEROID; COTRIMOXAZOLE; CREATININE; CYCLOPHOSPHAMIDE; ENALAPRIL; INFLIXIMAB; LOSARTAN; METHYLPREDNISOLONE; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; PREDNISOLONE; TRIMETHOPRIM; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; CASE REPORT; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FOLLOW UP; GLOMERULONEPHRITIS; HUMAN; HYPERTENSION; KIDNEY BIOPSY; KIDNEY FUNCTION; MAINTENANCE THERAPY; MALE; MORTALITY; OSTEOPOROSIS; PNEUMOCYSTOSIS; POLYARTHRITIS; PROTEINURIA; RAPIDLY PROGRESSIVE GLOMERULONEPHRITIS; REMISSION; RESPIRATORY TRACT INFECTION; SEPSIS; VIRUS INFECTION;

ADULT; ANTIBODIES; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; GLOMERULONEPHRITIS; HUMANS; KIDNEY; MALE; PEROXIDASE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 11344281443     PISSN: 02500868     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Jennette J.C., Falk R.J., Andrassy K., et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum, 37, 187, 1994.
2. Andrews M., Edmunds M., Campbell A., et al. Systemic vasculitis in the 1980s - is there an increasing incidence of Wegener's granulomatosis and microscopic polyarteritis? J.R. Coll. Physicians Lond., 24, 284, 1990.
3. Watts R.A., Jolliffe V.A., Carruthers D.M., et al. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum., 39, 1208, 1996.
4. Guillevin L., Durand-Gasselin B., Cevallos R., et al. Microscopic polyangiitis: Clinical and laboratory findings in eighty-five patients. Arthritis Rheum., 42, 421, 1999.
5. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculifis in mice. J. Clin. Invest., 110 955, 2002.
6. Heeringa P., Brouwer E., Tervaert J.W, et al. Animal models of anti-neutrophil cytoplasmic antibody associated vasculitis. Kidney Int., 53, 253, 1998.
7. Noronha I.L., Kruger C., Andrassy K., et al. In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. Kidney Int., 43(3), 682, 1993.
8. Vassalli P. The pathophysiology of tumor necrosis factors Annu. Rev. Immunol., 10, 411, 1992.
9. Feldmann M., Brennan F.M., Maini R. Cytokines in autoimmune disorders. Int. Rev. Immunol., 17, 217, 1998.
10. Tartaglia L.A., Ayres T.M., Wong G.H., et al. A novel domain within the 55 kd TNF receptor signals cell death. Cell, 74 845, 1993.
11. Lan H.Y. Therapeutic effects of cytokine blockade in glomerulonephritis. Nephrol. Dial. Transplant, 13, 7, 1998.
12. Jayne D. Evidence-based treatment of systemic vasculitis Rheumatology (Oxford), 39, 585, 2000.
13. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: An analysis of 158 patients. Ann. Intern. Med., 116 488, 1992.
14. Reinhold-Keller E., Beuge N., Latza U., et al. An interdisciplinary approach to the care of patients with Wegener's granulomatosis: Long-term outcome in 155 patients. Arthritis Rheum., 43. 1021, 2000.
15. Lamprecht P., Voswinkel J., Lilienthal T., et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford), 41, 1303, 2002.
16. Karkar A.M., Smith J., Pusey C.D. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumour necrosis factor-alpha. Nephrol. Dial. Transplant., 16, 518, 2001.
17. Sharp G.C., Irvin W.S., Tan E.M., et al. Mixed connective tissue disease - an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am. J. Med., 52, 148, 1972.
18. Luqmani R.A., Bacon P.A., Moots R.J., et al. Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis. QJM, 87, 671, 1994.
19. Guillevin L., Lhote F., Gayraud M., et al. Prognostic factors in polyarteritis nodosa and Churg-Strauss syndrome. A prospective study in 342 patients. Medicine (Baltimore), 75, 17, 1996.
20. Fauci A.S., Katz P., Haynes B.F., et al. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N. Engl. J. Med., 301, 235, 1979.
21. Specks U., Fervenza F.C., McDonald T.J., et al. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy. Arthritis Rheum., 44, 2836, 2001.
22. Gause A.M., Arbach O., Reinhold-Keller E., et al. Induction of remission with infliximab in active generalized Wegener's granulomatosis is effective but complicated by severe infections. Arthritis Rheum., 48, S208, 2003.
23. Bartolucci P., Ramanoelina J., Cohen P., et al. Efficacy of the anti-TNF-α antibody infliximab against refractory systemic vasculitides: An open pilot study on 10 patients. Rheumatology (Oxford), 41, 1126, 2002.
24. Booth A., Harper L., Hammad T., et al. Prospective study of TNF-α blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol., 15 717, 2004.
25. Franssen C.F., Stegeman C.A., Oost-Kort W.W., et al. Determinants of renal outcome in anti-myeloperoxidase-associated necrotizing crescentic glomerulonephritis. J. Am. Soc. Nephrol., 9 1915, 1998.
26. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet, 349, 1857, 1997.
27. Maschio G., Cagnoli L., Claroni F., et al. ACE inhibition reduces proteinuria in normotensive patients with IgA nephropathy: A multicentre, randomized, placebo-controlled study. Nephrol. Dial. Transplant., 9, 265, 1994.
28. Remuzzi G., Ruggenenti P., Benigni A. Understanding the nature of renal disease progression. Kidney Int., 51, 2, 1997.
29. Christopher-Stine L., Wigley F. Tumor necrosis factor-alpha antagonists induce lupus-like syndrome in patients with scleroderma overlap/mixed connective tissue disease. J. Rheumatol., 30, 2725, 2003.
30. Makita N., Katori H., Takemoto F., et al. A case of mixed connective tissue disease (MCTD) complicated with MPO-ANCA-related necrotizing glomerulonephritis. Clin. Nephrol., 54, 164, 2000.
31. Hassan A.B., Gunnarsson I., Karlsson G., et al. Longitudinal study of interleukin-10, tumor necrosis factor-alpha, anti-U1-snRNP antibody levels and disease activity in patients with mixed connective tissue disease. Scand. J. Rheumatol., 30, 282, 2001.
32. Principi M., Di Leo A., Ingrosso M., et al. Lupus nephritis improvement after anti-tumor necrosis factor alpha monoclonal antibody (infliximab) treatment for Crohn's disease: A case report. Immunopharmacol. Immunotoxicol., 26, 243, 2004.
33. Aringer M., Steiner G., Graninger W.B., et al. Clinical and immunological effects of anti-TNF therapy in systemic lupus erythematosus (SLE). Arthritis Res. Ther., 5, 33, 2003.